Effectiveness of XBB.1.5 vaccines against symptomatic SARS-CoV-2
infection in older adults during the JN.1 lineage-predominant period,
European VEBIS primary care multicentre study, 20 November 2023--1 March
2024
- Lore Merdrignac
, - Charlotte Laniece Delaunay,
- Nuno Verdasca,
- Lorena Vega Piris,
- Joan O'Donnell,
- Noémie Sève,
- Camino Trobajo-Sanmartín,
- Silke Buda,
- Mariette Hooiveld,
- Ana Paula Rodrigues,
- Gergő Túri,
- Neus Latorre-Margalef,
- Ivan Mlinarić,
- Mihaela Lazar,
- Marine Maurel,
- Daniel Castrillejo,
- Charlene Bennett,
- Marie-Anne Rameix-Welti,
- Iván Martínez-Baz,
- Ralf Dürrwald,
- Adam Meijer,
- Aryse Melo,
- Beatrix Oroszi,
- Tove Samuelsson Hagey,
- Sanja Kurečić Filipović,
- Frederika Dijkstra,
- Verónica Gómez,
- Sabrina Bacci,
- Marlena Kaczmarek,
- Esther Kissling
Nuno Verdasca
Instituto Nacional de Saude Doutor Ricardo Jorge Porto
Author ProfileNoémie Sève
Institut Pierre Louis d'Epidemiologie et de Sante Publique
Author ProfileCamino Trobajo-Sanmartín
Instituto de Salud Publica y Laboral de Navarra
Author ProfileMariette Hooiveld
Nederlands Instituut voor Onderzoek van de Gezondheidszorg
Author ProfileAna Paula Rodrigues
Instituto Nacional de Saude Doutor Ricardo Jorge IP Departamento de Doencas Infeciosas
Author ProfileGergő Túri
Semmelweis Egyetem Egeszsegugyi Menedzserkepzo Kozpont
Author ProfileIván Martínez-Baz
Instituto de Salud Publica y Laboral de Navarra
Author ProfileAdam Meijer
Rijksinstituut voor Volksgezondheid en Milieu Centrum Infectieziektebestrijding
Author ProfileAryse Melo
Instituto Nacional de Saude Doutor Ricardo Jorge Porto
Author ProfileBeatrix Oroszi
Semmelweis Egyetem Egeszsegugyi Menedzserkepzo Kozpont
Author ProfileFrederika Dijkstra
Rijksinstituut voor Volksgezondheid en Milieu Centrum Infectieziektebestrijding
Author ProfileVerónica Gómez
Instituto Nacional de Saude Doutor Ricardo Jorge IP Departamento de Doencas Infeciosas
Author ProfileSabrina Bacci
European Centre for Disease Prevention and Control
Author ProfileMarlena Kaczmarek
European Centre for Disease Prevention and Control
Author ProfileEsther Kissling
Epiconcept SAS
Corresponding Author:e.kissling@epiconcept.fr
Author ProfileAbstract
not-yet-known
not-yet-known
not-yet-known
unknown
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic
SARS-CoV-2 infection among adults aged ≥65 years during the 2023/24 JN.1
lineage-predominant period in a European multi-country test-negative
case-control study at primary care level. We estimated VE adjusted by
study site, age, sex, chronic conditions and onset date. We included 220
cases and 1733 controls. The VE was 48% (95% CI: 12–71), 23% (95%
CI: -11–48) and 5% (95% CI: -92–56) among those with symptom onset
1–5 , 6–11, and ≥12 weeks after vaccination, respectively. XBB.1.5
vaccine provided short and moderate protection against JN.1 symptomatic
infection.Submitted to Influenza and other respiratory viruses Submission Checks Completed
Assigned to Editor
Reviewer(s) Assigned
11 Aug 2024Review(s) Completed, Editorial Evaluation Pending
11 Aug 2024Editorial Decision: Revise Minor
23 Aug 20241st Revision Received
29 Aug 2024Submission Checks Completed
29 Aug 2024Assigned to Editor
29 Aug 2024Editorial Decision: Accept
